Compare Citius Pharmaceuticals Inc (CTXR) vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $64.59 (market cap $394.18M). The key difference: Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 is far larger — about 28.9× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 84,843). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 for 63 Days on average.
| CTXR | SLVO | |
|---|---|---|
Market Cap | $13.62M | $394.18M |
Volume | 132,438 | 84,843 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $107.41 |
52-Week Low | $0.48 | $61.81 |
Typical Hold Time | 17 Days | 63 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
SLVO trades at $64.59, up 1.62% today but remains in a bearish technical trend, with moving averages signaling continued downward pressure. Financial ratios are not available, limiting fundamental clarity. Recent news highlights the stock crossing below its 50-day moving average and links its performance to silver price declines, indicating sensitivity to commodity markets.
The outlook is cautious due to bearish technicals and commodity volatility. Opportunities exist if silver prices stabilize, but risks include dollar strength and lack of fundamental data. Investors should weigh technical recovery potential against macroeconomic headwinds affecting silver.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →
